RPV LA clinical trials

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

This study is testing a new, very long-acting injectable treatment for HIV. It's for adults and teenagers whose HIV is already well-controlled with daily pills. The study will compare how safe and effective this new injectable treatment is compared to other long-acting injections already available, to see if it can keep HIV under control.